Table 1.

Baseline patient characteristics.

N = 45
Age
 Median (range)68 (30–84)
 ≥65, n (%)24 (53.3)
Sex, n (%)
 Male24 (53.3)
 Female21 (46.7)
ECOG PS, n (%)
 026 (57.8)
 119 (42.2)
Previous treatment regimens, n (%)
 118 (40.0)
 ≥227 (60.0)
Primary cancer, n (%)
 Gastric18 (40.0)
 Colorectal17 (37.8)
 Cholangiocarcinoma5 (11.1)
 Small intestine2 (4.4)
 Pancreatic2 (4.4)
 Duodenal1 (2.2)
Metastatic sites, n (%)
 Liver9 (20.0)
 Lung7 (15.6)
 Lymph node35 (77.8)
 Peritoneum20 (44.4)
Number of metastatic organs, n (%)
 123 (51.1)
 ≥222 (48.9)
Treatment, n (%)
 Nivolumab8 (17.8)
 Pembrolizumab29 (64.4)
 Pembrolizumab with napabucasin8 (17.8)
TMB mutations/Mb, median (range)38.7 (3.6–93.0)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, Performance status.